EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers

Table 2 Ongoing EZH2 targeted clinical trials

Targeted Agent	Trade Name	Route	Trial	Tumor	Status/Adverse Events (Grade 3–4)	References
EPZ-6438	Tazemetostat	PO	Phase 1	NHL	Thrombocytopenia Neutropenia Hypertension Anorexia Transaminitis	[58]
		PO	Phase 1/2	B-cell lymphoma or advanced solid tumor	Recruiting actively	(Clinicaltrials.Gov. (2.13.2017)), (Epizyme pharmaceuticals website. (2.13.2017))
					NCT01897571
					Nausea
					Asthenia
					Thrombocytopenia
					Neutropenia
					Fatigue
		PO	Phase 1	Pediatric INI1 negative tumors or synovial sarcoma	Recruiting actively	(Clinicaltrials.Gov. (2.13.2017)), (Epizyme pharmaceuticals website. (2.13.2017))
		PO	Phase 1	Pediatric INI1 negative tumors or synovial sarcoma	NCT02601937
		PO	Phase 2	Adult INI1 negative tumors or synovial sarcoma	Recruiting actively	(Clinicaltrials.Gov. (2.13.2017)), (Epizyme pharmaceuticals website. (2.13.2017))
		PO	Phase 2	Adult INI1 negative tumors or synovial sarcoma	NCT02601950
		PO	Phase 2	Malignant mesothelioma	Recruiting actively	(Clinicaltrials.Gov. (2.13.2017)), (Epizyme pharmaceuticals website. (2.13.2017))
		PO	Phase 2	Malignant mesothelioma	NCT02860286
GSK 2,816,126	GSK126	IV	Phase 1/2	Diffuse large B-cell lymphoma	Fatigue	[59]
					Nausea
					Vomiting
					Anemia
EPZ-5676	Pinometostat	IV	Phase 1	Leukemia	Hypophosphatemia	[60]
					Neutropenia
					Reduced ejection fraction
					Transaminitis
CPI-1205		IV	Phase 1	B cell lymphoma	Recruiting actively	(Clinicaltrials.Gov. (2.13.2017)),
CPI-1205		IV	Phase 1	B cell lymphoma	NCT02395601	(Clinicaltrials.Gov. (2.13.2017)),

ISSN: 2053-6844